Regulus Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery and development of innovative medicines targeting microRNAs. The company, also known as Regulus,

Bayer and the Broad Institute of MIT and Harvard recently announced the extension of their research partnership for another five years, following a decade of successful collaboration. This renewed agreement

Kyverna Therapeutics, a clinical-stage company specializing in cell therapy and focused on developing innovative treatments for severe autoimmune diseases, has recently entered into a multi-year research funding agreement

Prelude Therapeutics Incorporated and AbCellera have recently unveiled a multi-year, multi-program partnership aimed at the exploration, advancement, and market launch of innovative treatments for cancer patients.

Chimeric Therapeutics, an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for CHM 2101, the company's first-in-class CDH17 CAR T cell therapy

Oncoinvent AS, a company in the clinical stage focused on advancing alpha emitter therapy for various solid cancers, has officially received approval from the U.S. Food and Drug Administration for its Investigational New Drug

Transpire Bio's commitment to Florida and the establishment of a biomanufacturing workforce in Weston. She envisioned this move as a potential opportunity to position South Florida at the forefront of the life sciences industry.

AnHeart Therapeutics, a global clinical-stage biopharmaceutical company, has recently established an exclusive license agreement with Nippon Kayaku Co., Ltd for the marketing and distribution of their lead investigational therapy.

Biophytis SA, a biotechnology company in the clinical development stage listed on Nasdaq CM and Euronext Growth Paris, specializes in the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving

Oncternal Therapeutics, Inc, is a clinical-stage biopharmaceutical company dedicated to developing novel oncology treatments. They recently announced that the U.S. Food and Drug Administration has granted Fast Track designation for ONCT-534.